TriangleDISEASE & TREATMENT SETTING
Chronic Lymphocytic Leukemia
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Chronic Lymphocytic Leukemia
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Derived from NCI topic(s): Chronic Lymphocytic Leukemia. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
14 more-specific settings
Breyanzi: refractory Chronic Lymphocytic Leukemia after prior therapy →Arzerra: refractory Chronic Lymphocytic Leukemia →Imbruvica: Chronic Lymphocytic Leukemia after prior therapy →Jayprica: Chronic Lymphocytic Leukemia after prior therapy →Venclexta: Chronic Lymphocytic Leukemia after prior therapy →Oforta: B-Cell CLL after prior therapy →Rituxan Hycela: refractory Chronic Lymphocytic Leukemia (first-line) after prior therapy →Zydelig: recurrent Chronic Lymphocytic Leukemia →COPIKTRA: refractory Chronic Lymphocytic Leukemia after prior therapy →BREYANZI: refractory Chronic Lymphocytic Leukemia after prior therapy →JAYPIRCA: refractory Chronic Lymphocytic Leukemia →COPIKTRA: refractory Chronic Lymphocytic Leukemia after prior therapy →Imbruvica: Chronic Lymphocytic Leukemia after prior therapy →recurrent Chronic Lymphocytic Leukemia →
Study evidence for this setting
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematolog
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
Post Transplant Donor Lymphocyte Infusion
Stem Cell Transplant for Hematological Malignancy
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Indication-specific source history
2001-05-07 · Campath (alemtuzumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-a2bc5d23b08a3967
- event date
- 2001-05-07
- event kind
- accelerated-approval
- drug or regimen
- Campath (alemtuzumab)
- source indication text
- B-cell CLL treated with alkylating agents and failed fludarabine therapy
- match phrase
- b-cell cll
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-5a19a4308263acf29337
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2007-09-19 · Campath (alemtuzumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-bdc7482b89c6940e
- event date
- 2007-09-19
- event kind
- traditional-approval
- drug or regimen
- Campath (alemtuzumab)
- source indication text
- B-cell CLL treated with alkylating agents and failed fludarabine therapy
- match phrase
- b-cell cll
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-5a19a4308263acf29337
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2008-12-18 · Oforta (fludarabine phosphate) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-4a8825ca527dcca6
- event date
- 2008-12-18
- event kind
- accelerated-approval
- drug or regimen
- Oforta (fludarabine phosphate)
- source indication text
- For adults with B-cell CLL that has not responded to or progressed during or after treatment with at least one standard alkylating agent containing regimen
- match phrase
- b-cell cll
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-50e1693b2912039de2b3
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2009-10-26 · Arzerra (ofatumumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-327601cff6808bcc
- event date
- 2009-10-26
- event kind
- accelerated-approval
- drug or regimen
- Arzerra (ofatumumab)
- source indication text
- Chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab
- match phrase
- chronic lymphocytic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-4ac21c1dd7ac861dae8d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2011-12-31 · Oforta (fludarabine phosphate) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-8917865283d831f3
- event date
- 2011-12-31
- event kind
- withdrawal
- drug or regimen
- Oforta (fludarabine phosphate)
- source indication text
- For adults with B-cell CLL that has not responded to or progressed during or after treatment with at least one standard alkylating agent containing regimen
- match phrase
- b-cell cll
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-50e1693b2912039de2b3
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2014-02-12 · Imbruvica (ibrutinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-8660a287a573b22c
- event date
- 2014-02-12
- event kind
- accelerated-approval
- drug or regimen
- Imbruvica (ibrutinib)
- source indication text
- Chronic lymphocytic leukemia after at least one prior therapy
- match phrase
- chronic lymphocytic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-6231c98cea2f27ce3f56
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2014-04-17 · Arzerra (ofatumumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-a8a643e378b874bb
- event date
- 2014-04-17
- event kind
- traditional-approval
- drug or regimen
- Arzerra (ofatumumab)
- source indication text
- Chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab
- match phrase
- chronic lymphocytic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-4ac21c1dd7ac861dae8d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2014-07-28 · Imbruvica (ibrutinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-67d4fa20db32c9fb
- event date
- 2014-07-28
- event kind
- traditional-approval
- drug or regimen
- Imbruvica (ibrutinib)
- source indication text
- Chronic lymphocytic leukemia after at least one prior therapy
- match phrase
- chronic lymphocytic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-6231c98cea2f27ce3f56
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2016-04-11 · Venclexta (venetoclax) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-ba1bb11d63eb5f2d
- event date
- 2016-04-11
- event kind
- accelerated-approval
- drug or regimen
- Venclexta (venetoclax)
- source indication text
- Chronic lymphocytic leukemia with 17P deletion as detected by an FDA-approved test, after at least one prior therapy
- match phrase
- chronic lymphocytic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-53da3fe02d37c0867b7e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2018-06-08 · Venclexta (venetoclax) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-5b602f3762f8a6f7
- event date
- 2018-06-08
- event kind
- traditional-approval
- drug or regimen
- Venclexta (venetoclax)
- source indication text
- Chronic lymphocytic leukemia with 17P deletion as detected by an FDA-approved test, after at least one prior therapy
- match phrase
- chronic lymphocytic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-53da3fe02d37c0867b7e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2023-12-01 · Jayprica (pirtobrutinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-d5befa963912c831
- event date
- 2023-12-01
- event kind
- accelerated-approval
- drug or regimen
- Jayprica (pirtobrutinib)
- source indication text
- Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor
- match phrase
- chronic lymphocytic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-f46040f9a05ea161be30
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-03-21 · Breyanzi (lisocabtagene maraleucel) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-5ac677ed2d82e228
- event date
- 2024-03-21
- event kind
- accelerated-approval
- drug or regimen
- Breyanzi (lisocabtagene maraleucel)
- source indication text
- Adult patients with relapsed/ refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least two prior lines of therapy including a Bruton’s tyrosine kinase (BTK) inhibitor and a B-cell lymphoma-2 (BCL-2) inhibitor
- match phrase
- chronic lymphocytic leukemia
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-75ffcc7a7a2999eed44d
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-12-02 · Jayprica (pirtobrutinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- fda-085a9660609cb09b
- event date
- 2025-12-02
- event kind
- traditional-approval
- drug or regimen
- Jayprica (pirtobrutinib)
- source indication text
- Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor
- match phrase
- chronic lymphocytic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-f46040f9a05ea161be30
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-12-03 · pirtobrutinib · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- notice-3c5cebfc43b45b02
- event date
- 2025-12-03
- event kind
- approval-notification
- drug or regimen
- pirtobrutinib
- source indication text
- FDA approved pirtobrutinib for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
- match phrase
- chronic lymphocytic leukemia
- match status
- candidate
- status category
- traditional
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-a90b83cba53cf44c
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-02-19 · acalabrutinib with venetoclax · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- event id
- notice-d847d4cd8dfbbe45
- event date
- 2026-02-19
- event kind
- approval-notification
- drug or regimen
- acalabrutinib with venetoclax
- source indication text
- FDA approved acalabrutinib tablets and capsules in combination with venetoclax for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma .
- match phrase
- chronic lymphocytic leukemia
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-2484637c7ad88112
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-lymphocytic-leukemia
- binding id
- ncit-C3163
- source collection
- ncit-concept
- source key
- C3163
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice